Today at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology, Phadia US introduced two new products designed specifically to meet the unique needs of the nation’s 6,000 allergists.
ImmunoCAP ISAC and ImmunoCAP HR are new offerings designed to augment traditional allergy testing methodologies and enable diagnosis of complex food allergies at the molecular level, available through its own PiRL testing facility.
Immuno Solid-phase Allergy Chip, or ISAC, is a multi-array technology package designed to provide a detailed assessment of specific allergies as part of the initial patient assessment and workup. With ISAC, allergists can test for the particular molecular components driving the allergic disease process in patients. As a result, allergists can identify precisely those patients in danger of severe allergic reaction to allergens such as peanut, wheat, or egg and many others.
ISAC uses a small sample of blood to produce results for 103 components representing a wide spectrum of allergens. With this additional information, the allergist can then identify the unique sensitization patterns for every patient, enabling the development of a personalized allergy management plan.
In addition to the technology announced above, Phadia is proud to announce the availability of ImmunoCAP HR, utilizing proven ImmunoCAP solid phase technology. ImmunoCAP HR provides Highly Refined specific allergen component testing so that doctors can assess a patients’ relative risk for allergy symptoms through better characterization of the precise quantitation of specific IgE antibodies to various allergen components. With this technology, clinicians will be able to define the patient’s sensitization to specific allergen components.